UNSPSC 51292702: Encyprate

This classification denotes an antidepressant agent with the molecular formula C13H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26991ZCA4G, chemically known as cyclopropanecarbamic acid, n-benzyl-, ethyl ester but generally known as encyprate, which bears US NIH Compound Identifier 17298. European Medicines Agency schedules Encyprate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06522MIG. The term ENCYPRATE is an International Non-Proprietary Name.

UNSPSC 51292702 Encyprate is a Commodity-tier code that captures pharmaceutical products and drug-related supplies state and local governments procure for community health, emergency response, and pharmacy benefit programs. State and local buyers use this code to solicit naloxone and drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription fulfillment solutions. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP). The mix reflects both direct county procurement for community health initiatives and state-level aggregated purchasing through cooperative vehicles that serve multiple jurisdictions and subordinate government entities.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP procurement extending to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries through July 2023 (IFB60459723LAS); the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs issued April 3, 2026 (HHS0017013) to explore vendor capabilities for establishing state pharmacy benefit relationships outside traditional pharmacy benefit managers and group purchasing organizations; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026 (S1070000015802), requiring vendor compliance with cGMP and Drug Supply Chain Security Act standards, relationships with authorized wholesalers including AmerisourceBergen and Cardinal Health, and performance guarantees with administrative fees of three percent. Cooperative purchasing opportunities typically impose higher insurance and regulatory compliance thresholds than single-jurisdiction solicitations, with contract terms ranging from two years plus optional extensions to annual renewable agreements.